Inhibition of Rho-associated kinase 1/2 attenuates tumor growth in murine gastric cancer

• Verfasst von: Hinsenkamp, Isabel [VerfasserIn]
• Verfasst von: Roscher, Mareike [VerfasserIn]
• Verfasst von: Schönberg, Stefan [VerfasserIn]
• Verfasst von: Ebert, Matthias [VerfasserIn]
• Verfasst von: Wängler, Björn [VerfasserIn]
• Verfasst von: Hopf, Carsten [VerfasserIn]
• Verfasst von: Burgermeister, Elke [VerfasserIn]
• Titel: Inhibition of Rho-associated kinase 1/2 attenuates tumor growth in murine gastric cancer
• Verf.angabe: Isabel Hinsenkamp, Sandra Schulz, Mareike Roscher, Anne-Maria Suhr, Björn Meyer, Bogdan Munteanu, Jens Fuchser, Stefan O. Schoenberg, Matthias P.A. Ebert, Björn Wängler, Carsten Hopf and Elke Burgermeister
• E-Jahr: 2016
• Jahr: August 2016
• Umfang: 12 S.
• Fussnoten: Gesehen am 26.08.2019
• Titel Quelle: Enthalten in: Neoplasia
• Ort Quelle: Basingstoke : Stockton Press, 1999
• Jahr Quelle: 2016
• Band/Heft Quelle: 18(2016), 8, Seite 500-511
• ISSN Quelle: 1476-5586
• DOI: doi:10.1016/j.neo.2016.07.002
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1672148863

Abstract

Gastric cancer (GC) remains a malignant disease with high mortality. Patients are frequently diagnosed in advanced stages where survival prognosis is poor. Thus, there is high medical need to find novel drug targets and treatment strategies. Recently, the comprehensive molecular characterization of GC subtypes revealed mutations in the small GTPase RHOA as a hallmark of diffuse-type GC. RHOA activates RHO-associated protein kinases (ROCK1/2) which regulate cell contractility, migration and growth and thus may play a role in cancer. However, therapeutic benefit of RHO-pathway inhibition in GC has not been shown so far. The ROCK1/2 inhibitor 1-(5-isoquinoline sulfonyl)-homopiperazine (HA-1077, fasudil) is approved for cerebrovascular bleeding in patients. We therefore investigated whether fasudil (i.p., 10 mg/kg per day, 4 times per week, 4 weeks) inhibits tumor growth in a preclinical model of GC. Fasudil evoked cell death in human GC cells and reduced the tumor size in the stomach of CEA424-SV40 TAg transgenic mice. Small animal PET/CT confirmed preclinical efficacy. Mass spectrometry imaging identified a translatable biomarker for mouse GC and suggested rapid but incomplete in situ distribution of the drug to gastric tumor tissue. RHOA expression was increased in the neoplastic murine stomach compared with normal non-malignant gastric tissue, and fasudil reduced (auto) phosphorylation of ROCK2 at THR249 in vivo and in human GC cells in vitro. In sum, our data suggest that RHO-pathway inhibition may constitute a novel strategy for treatment of GC and that enhanced distribution of future ROCK inhibitors into tumor tissue may further improve efficacy.